Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
Public ClinicalTrials.gov record NCT05008224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary hypothesis of the study is that the complete response (CR) rate at the end of study intervention according to Lugano 2014 response criteria is higher than conventional chemotherapy.
Study identification
- NCT ID
- NCT05008224
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 146 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Doxorubicin Drug
- Vinblastine Drug
- Dacarbazine Drug
- Bleomycin Drug
- Etoposide Drug
- Cyclophosphamide Drug
- Vincristine Drug
- Procarbazine Drug
- Prednisone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2021 (Actual)
- Primary completion
- Oct 11, 2023 (Actual)
- Completion
- May 26, 2024 (Actual)
- Last update posted
- Jun 6, 2025
2021 – 2024
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St Joseph Heritage Healthcare-Oncology ( Site 0004) | Fullerton | California | 92835 | — |
| Stanford Cancer Center ( Site 0023) | Palo Alto | California | 94304 | — |
| Northwestern Memorial Hospital ( Site 0002) | Chicago | Illinois | 60611 | — |
| OptumCare Cancer Care-Research Department ( Site 0005) | Las Vegas | Nevada | 89102 | — |
| University of Tennessee Medical Center-Cancer Institute ( Site 0006) | Knoxville | Tennessee | 37920 | — |
| Texas Oncology-Plano East ( Site 0020) | Plano | Texas | 75075 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05008224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05008224 live on ClinicalTrials.gov.